Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.
You may also be interested in...
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.